To Change Medicine Right now.

CIRM established the Industry Alliance Program (IAP) as a direct opportunity for the industry to partner with CIRM in accelerating the most promising stem cell, gene and regenerative medicine therapy programs to commercialization. Through the IAP, CIRM is a dedicated and proactive partner to industry and CIRM grantees.


Click on logos below to learn more

Contact Us To
Learn More Today

Shyam Patel, Ph.D.,
Director, Business Development

One of the greatest strengths of CIRM has been their focus on development of new stem cell therapies that can become real medicines. This support has allowed the stem cell gene therapy we developed to treat SCID babies to be advanced."

CIRM grantees drew in over $8B
in biopharma industry partnerships.